Efficacy and Safety of Tapentadol Immediate Release Assessment in Treatment of Moderate to Severe Pain: A Systematic Review and Meta-Analysis

Objective. To assess the efficacy and safety of tapentadol IR for moderate to severe pain compared to oxycodone IR. Methods. A search was carried out up to July 2015 for randomized controlled trials (RCTs) of tapentadol IR compared to placebo or oxycodone HCL IR 10 mg for moderate to severe pain. St...

Full description

Saved in:
Bibliographic Details
Published in:Pain medicine (Malden, Mass.) Mass.), 2017-01, Vol.18 (1), p.14-24
Main Authors: Xiao, Jing-Ping, Li, Ai-Ling, Feng, Bi-Min, Ye, Yun, Wang, Guo-Jun
Format: Article
Language:English
Subjects:
Analgesics - therapeutic use
Constipation
Evidence-based medicine
Humans
Meta-analysis
Nausea
Oxycodone
Pain
Pain - drug therapy
Phenols - therapeutic use
Randomized Controlled Trials as Topic
Statistical analysis
Systematic review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective. To assess the efficacy and safety of tapentadol IR for moderate to severe pain compared to oxycodone IR. Methods. A search was carried out up to July 2015 for randomized controlled trials (RCTs) of tapentadol IR compared to placebo or oxycodone HCL IR 10 mg for moderate to severe pain. Studies were pooled by risk ratio (RR) and weighted mean differences (WMD) with 95% confidence interval (CI). Results. Nine RCTs (n = 3,961) were analyzed. In this meta-analysis, tapentadol IR (50-, 75-, and 100-mg doses) showed significant improvements in moderate to severe pain relief on the sum of pain intensity difference over 48 hours (SPID48) scores (P  0.05) was found. Compared with tapentadol IR 50 mg, tapentadol IR 75 mg demonstrated significant improvement in moderate to severe pain relief based on both SPID48 and TOTPAR48 scores (all P 
ISSN:1526-2375
1526-4637
DOI:10.1093/pm/pnw154